Yellow autofluorescence of the retinal pigment epithelium (RPE) due to the accumulation of lipofuscin in the human retina.
Image courtesy of Robert Mullins, PhD, University of Iowa.
Matthew Feinsod, MD, Co-founder, Chief Medical Officer
Matthew Feinsod, MD, was SVP of Strategy and Product Development at Eyetech Pharmaceuticals where he spent five years in a variety of functions helping to develop Macugen and preclinical programs. Prior to joining Eyetech, Matt served as medical officer at the U.S. Food & Drug Administration (FDA), Division of Anti-inflammatory, Analgesic and Ophthalmologic Drug Products. There, he was a primary reviewer for both IND and NDA ophthalmology applications. Concurrently, he held a clinical trials/drug development fellowship position in George Washington University's Department of Ophthalmology and served on the hospital's Institutional Review Board. Previously, Matt conducted post-doctoral molecular biology research with a focus on nucleotide science at Cornell University Medical Center.
Matt received his MD from the George Washington University School of Medicine and his undergraduate degree from the Wharton School of Business. He completed his residency at the Manhattan Eye, Ear and Throat Hospital and is board-certified in ophthalmology. Matt holds several patents in the field of ophthalmology and in emitted light-stabilization. He is founder of Transmedical Corporation, a medical publishing/marketing company, and co-founder of Gyrotech LLC, developer of light-stabilization technology.
Scott W. Cousins, MD, Chief Scientific Officer
Scott W. Cousins, MD, is a retina-trained ophthalmologist and clinician scientist. During his academic career, Scott has been active in both clinical and laboratory research. In his scientific laboratory, Scott has pursued both NIH-funded and industry-funded research in various areas of dry and wet AMD. In particular, his laboratory established one of the first mouse models for early AMD, and he has been a leader in understanding the role of oxidant-induced injury responses and inflammation in AMD. In his clinical practice, Scott has been involved in many clinical trials and innovative therapies for the treatment of macular diseases, especially AMD. Scott has published over 100 peer-reviewed manuscripts, book chapters, and other publications addressing topics of research or clinical care of retinal disease, especially AMD.
Scott is currently the Robert Machemer, M.D. Professor of Ophthalmology and Immunology, Vice Chair for Research, and Director of the Duke Center for Macular Diseases at Duke Eye Center, Duke University School of Medicine. Prior to joining Duke University, Scott was Anne Bates Leach Professor of Ophthalmology at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. Scott has received numerous awards, including the Research to Prevent Blindness Dolly Green Scholar Award, the Lew Wasserman Merit Award and the Alcon Research Foundation Clinician Scientist Award. He is a Fellow of the Association for Research in Vision and Ophthalmology. Between 2008-2011, Scott served on the National Advisory Eye Council for the National Eye Institute. Scott is a member of the American Academy of Ophthalmology, the American Society of Retina Specialists, the Retina Society, the Association for Research in Vision and Ophthalmology, the American Association of Immunologists, and the American Medical Association. Scott will retain his academic position at Duke University while serving as Chief Scientific Officer.
David Guyer, MD, Co-founder, Executive Chairman
David Guyer, MD, is a retina-trained ophthalmologist and pioneer in ophthalmology drug development. David joined SV Life Sciences in 2006 and serves on the Boards of portfolio companies Link Medicine, Lux Biosciences, NeoVista, Neurotech, Ophthotech and Panoptica.
David co-founded and served as CEO and director for six years at Eyetech Pharmaceuticals (former Ticker 'EYET'), Inc. a biopharmaceutical company that specialized in the development and commercialization of novel therapeutics to treat diseases of the eye. He led the firm through private financing rounds totaling approximately $170 million, a $157 million initial public offering and a secondary financing. Eyetech reached a peak market cap of approximately $2 billion dollars. The company also developed and gained FDA approval for Macugen, a product to treat macular degeneration, which Eyetech partnered with Pfizer in a deal valued at over $750 million. OSI Pharmaceuticals subsequently acquired Eyetech in a deal valued at $935 million. Prior to founding Eyetech, David was professor and chairman of the department of ophthalmology at the NYU School of Medicine.
David received a BSc from Yale College and an MD from Johns Hopkins Medical School.
Ashish Khanna, PhD, Principal, SV Life Sciences
Ash Khanna, PhD, joined SV Life Sciences in 2005 as a Kauffman Fellow and is focused on therapeutics, diagnostics and other life sciences investments. Ash is a board observer or actively involved with the following portfolio companies: Allocure, Good Start Genetics, Logical Therapeutics, Mpex Pharma, NKT Therapeutics, Panoptica and Sutro BioPharma.
Previously, Ash was a Team Leader at Bristol-Myers Squibb, where his primary responsibility was the clinical advancement of anti-diabetic agents. Ash led the Preclinical Development Team that discovered Onglyza (Saxagliptin), a DPP-4 inhibitor that is currently marketed for the treatment of Type 2 diabetes. Ash has also co-founded and served as the Chief Business Officer of IntuiTouch, a medical device company that harnesses near-infra red technology for the detection of breast cancer.
Ash earned a PhD in Pharmaceutics from the State University of New York and an MBA (Finance) from the Wharton School. He has a BS (Pharmacy) from the University of Bombay.
Thomas Dyrberg, MD, Senior Partner, Novo Ventures, Novo A/S.
Thomas Dyrberg, MD, joined Novo A/S in 2000. He is a member of the boards of directors of AlloCure Inc., Delenex Therapeutics AG, LifeCycle Pharma A/S, Lux Biosciences Inc. and Ophthotech Corporation, and was a board member of BioMimetic Therapeutics, Inc., Gloucester Pharmaceuticals, HemoFocus ApS and Sapphire Therapeutics, Inc.
Thomas held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, USA. In 1990, he joined Novo Nordisk A/S, initially working in Health Care Discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in Health Care Clinical Drug Development as an International Clinical Project Manager.
Thomas obtained an MD degree from the University of Copenhagen in 1981 and a DMSc degree, also from the University of Copenhagen in 1986.
Hingge Hsu, MD, Partner, Fidelity Biosciences
Hingge Hsu, MD, joined Fidelity Biosciences as a Venture Partner in April 2009. Most recently he was a Managing Director at Lehman Brothers in their Private Equity Group, responsible for their principal investment activities in the private and public sectors of the healthcare industry. Prior to that, he was a Partner at Schroder Ventures Life Sciences from 1998 to 2001 and directed their US investment activities in the life sciences and therapeutics sectors. Hingge was also a Principal at Robertson Stephens in the Healthcare Investment Banking Group and worked at Chiron Corporation and Gensia, Inc. in the areas of business development and strategic planning.
Hingge received an MD degree from Yale University School of Medicine and was trained in internal medicine at Brigham and Women's Hospital and Harvard Medical School. He also received an MBA degree from Harvard Business School.
Hingge serves on the Board of Directors of NextWave Pharmaceuticals and Fluidnet.